Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Jing-biao Wu, Ya-ling Tang & Xin-hua Liang. (2018) Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy. OncoTargets and Therapy 11, pages 6901-6909.
Read now
Read now
M. Tampellini, A. La Salvia & G. V. Scagliotti. (2016) Novel investigational therapies for treating biliary tract carcinoma. Expert Opinion on Investigational Drugs 25:12, pages 1423-1436.
Read now
Read now
Giuseppe Aprile, Laura Ferrari, Chiara Cremolini, Francesca Bergamo, Caterina Fontanella, Francesca Battaglin, Karim Rihawi, Sara Lonardi, Fotios Loupakis & Mario Scartozzi. (2016) Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. Expert Review of Clinical Pharmacology 9:7, pages 877-885.
Read now
Read now
Florentina Serban, Stefan-Alexandru Artene, Ada Maria Georgescu, Stefana Oana Purcaru, Daniela Elise Tache, Oana Alexandru & Anica Dricu. (2015) Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker. OncoTargets and Therapy 8, pages 3767-3774.
Read now
Read now
Giuseppe Aprile, Francesco Leone, Riccardo Giampieri, Mariaelena Casagrande, Donatella Marino, Luca Faloppi, Stefano Cascinu, Gianpiero Fasola & Mario Scartozzi. (2015) Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. OncoTargets and Therapy 8, pages 1149-1156.
Read now
Read now
Omar Abdel-Rahman & Hesham ElHalawani. (2015) Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis. Expert Opinion on Drug Safety 14:10, pages 1495-1506.
Read now
Read now
Sara Pilotto, Silvia Novello, Umberto Peretti, Stefania Kinspergher, Ludovica Ciuffreda, Michele Milella, Luisa Carbognin, Tiziana Vavalà, Roberto Ferrara, Mario Caccese, Giampaolo Tortora & Emilio Bria. (2015) An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer. Expert Opinion on Investigational Drugs 24:9, pages 1143-1161.
Read now
Read now
Clarisse R Mazzola & Joseph Chin. (2015) Targeting the VEGF pathway in metastatic bladder cancer. Expert Opinion on Investigational Drugs 24:7, pages 913-927.
Read now
Read now
Articles from other publishers (33)
Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer
413
458
.
Alice Bellini, Beatrice Aramini & Franco Stella. 2022. Mesothelioma - Diagnostics, Treatment and Basic Research. Mesothelioma - Diagnostics, Treatment and Basic Research.
Chunping Cai, Xiaoji Wang, Qiurong Fu & Ai Chen. (2022) The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. World Journal of Surgical Oncology 20:1.
Crossref
Crossref
Ajmal Ahmad & Mohd Imtiaz Nawaz. (2022) Molecular mechanism of VEGF and its role in pathological angiogenesis. Journal of Cellular Biochemistry 123:12, pages 1938-1965.
Crossref
Crossref
Roberto Tamma, Tiziana Annese & Domenico Ribatti. 2022. The Extracellular Matrix and the Tumor Microenvironment. The Extracellular Matrix and the Tumor Microenvironment
375
397
.
Sezer Akgol, Batuhan Mert Kalkan, Dogacan Yucel & Fatih Kocabas. (2021) SC1 limits tube formation, branching, migration, expansion and induce apoptosis of endothelial cells. Vascular Pharmacology 141, pages 106903.
Crossref
Crossref
Ming-Huang Chen, Sheng-Nan Lu, Chien-Hung Chen, Peng-Chan Lin, Jeng-Kai Jiang, Yulia D’yachkova, Mariusz Lukanowski, Rebecca Cheng & Li-Tzong Chen. (2021) How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?. Cancers 13:14, pages 3536.
Crossref
Crossref
Jole Ventriglia, Immacolata Paciolla, Carmela Pisano, Rosa Tambaro, Sabrina Chiara Cecere, Marilena Di Napoli, Laura Attademo, Laura Arenare, Anna Spina, Daniela Russo, Daniela Califano, Nunzia Simona Losito, Sergio Venanzio Setola, Elisena Franzese, Ferdinando De Vita, Michele Orditura & Sandro Pignata. (2021) Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy. International Journal of Gynecologic Cancer 31:1, pages 110-113.
Crossref
Crossref
Nianwu Wang, Wei Wang, Wenli Mao, Kefeng Wang, Haozhe Zhang, Qiang Ma, Nazuke Kuerbantayi & Yukun Wang. (2021) New Approved First-line Combining Therapy of NSCLC in 2020. E3S Web of Conferences 245, pages 03057.
Crossref
Crossref
Domenico Ribatti. 2021. Tumor Microenvironment Regulation of Tumor Expansion. Tumor Microenvironment Regulation of Tumor Expansion
139
154
.
Ji-Hak Jeong, Uttam Ojha & You Mie Lee. (2020) Pathological angiogenesis and inflammation in tissues. Archives of Pharmacal Research 44:1, pages 1-15.
Crossref
Crossref
Shi Zhou & Haijun Zhang. (2020) Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications. Anti-Cancer Agents in Medicinal Chemistry 20:7, pages 768-776.
Crossref
Crossref
Katarzyna Sobierajska, Wojciech Michal Ciszewski, Izabela Sacewicz-Hofman & Jolanta Niewiarowska. 2020. Tumor Microenvironment. Tumor Microenvironment
71
86
.
Xiaobo Li, Yong Li, Weijin Lu, Minfeng Chen, Wencai Ye & Dongmei Zhang. (2019) The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis. Cells 8:12, pages 1602.
Crossref
Crossref
Jung-A Yun, Joohwan Kim, Yi-Yong Baek, Wonjin Park, Minsik Park, Suji Kim, Taesam Kim, Seunghwan Choi, Dooil Jeoung, Hansoo Lee, Moo-Ho Won, Ji-Yoon Kim, Kwon-Soo Ha, Young-Guen Kwon & Young-Myeong Kim. (2019) N-Terminal Modification of the Tetrapeptide Arg-Leu-Tyr-Glu, a Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Antagonist, Improves Antitumor Activity by Increasing its Stability against Serum Peptidases. Molecular Pharmacology 96:6, pages 692-701.
Crossref
Crossref
Aejaz Nasir. 2019. Predictive Biomarkers in Oncology. Predictive Biomarkers in Oncology
243
262
.
Elaine Vickers. 2018. A Beginner's Guide to Targeted Cancer Treatments. A Beginner's Guide to Targeted Cancer Treatments
111
150
.
Paul A. Moore, Ross La Motte‐Mohs, Jonathan C. Li & Gurunadh R. Chichili. 2017. Protein Therapeutics. Protein Therapeutics
521
585
.
Khalid Abu Ajaj. (2017) A decade of targeted therapy for non-small cell lung cancer. Journal of Pulmonology and Respiratory Research 1:1, pages 023-027.
Crossref
Crossref
Marta Schirripa, Heinz-Josef Lenz & Stefan J. Scherer. 2017. Cancer Therapeutic Targets. Cancer Therapeutic Targets
639
658
.
Ewa Maj, Diana Papiernik & Joanna Wietrzyk. (2016) Antiangiogenic cancer treatment: The great discovery and greater complexity (Review). International Journal of Oncology 49:5, pages 1773-1784.
Crossref
Crossref
Benjamin F. Chu & Gregory A. Otterson. (2016) Incorporation of Antiangiogenic Therapy Into the Non–Small-Cell Lung Cancer Paradigm. Clinical Lung Cancer 17:6, pages 493-506.
Crossref
Crossref
Grigoris T. Gerotziafas & Ismail Elalamy. (2016) Risque thromboembolique en oncologie : réalités, actualités et perspectives. Bulletin du Cancer 103:9, pages 764-775.
Crossref
Crossref
Mei Liu, Zhiyang Li, Jingjing Yang, Yanyun Jiang, Zhongsi Chen, Zeeshan Ali, Nongyue He & Zhifei Wang. (2016) Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment. Cell Proliferation 49:4, pages 409-420.
Crossref
Crossref
Jennifer Grabowski & Ashley Glode. (2016) Ramucirumab: A vascular endothelial growth factor receptor-2 inhibitor with activity in several malignancies. American Journal of Health-System Pharmacy 73:13, pages 957-968.
Crossref
Crossref
Fan-Wei Peng, Ji Xuan, Ting-Ting Wu, Jia-Yu Xue, Zi-Wei Ren, Da-Ke Liu, Xiu-Qi Wang, Xin-Hang Chen, Jia-Wei Zhang, Yun-Gen Xu & Lei Shi. (2016) Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC. European Journal of Medicinal Chemistry 109, pages 1-12.
Crossref
Crossref
Ozan Yazici. (2016) Targeted therapies in gastric cancer and future perspectives. World Journal of Gastroenterology 22:2, pages 471.
Crossref
Crossref
H. Büning & U. T. Hacker. 2016. Protein Targeting Compounds. Protein Targeting Compounds
261
285
.
Marta Schirripa, Heinz-Josef Lenz & Stefan J. Scherer. 2016. Cancer Therapeutic Targets. Cancer Therapeutic Targets
1
20
.
Ingrid Moen, Matthew Gebre, Vanesa Alonso-Camino, Debbie Chen, David Epstein & Donald M. McDonald. (2015) Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors. Clinical & Experimental Metastasis 32:8, pages 799-817.
Crossref
Crossref
Omar Abdel-Rahman & Hesham ElHalawani. (2015) Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis. Future Oncology 11:21, pages 2949-2961.
Crossref
Crossref
H. Büning & U. T. Hacker. 2015. Protein Targeting Compounds. Protein Targeting Compounds
261
285
.
Omar Abdel-Rahman & Hesham ElHalawani. (2014) Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-Analysis. Chemotherapy 60:5-6, pages 325-333.
Crossref
Crossref